SEARCH

SEARCH BY CITATION

References

  • Alam K, Butlin CR, Pahan D, Kumar S & Chowdhury (2007) Long-term follow-up of ROM treated cases. Leprosy Review 78, 160.
  • Altman DG & Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326, 219.
  • Babu GR, Edward VK, Gupte MD et al. (1997) Efficacy of single-dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Leprosy Review 68, 341349.
  • Begg CB & Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 10881101.
  • Cooper H & Hedges L (1994) The Handbook of Research Synthesis. Russell Sage Foundation, New York, NY.
  • Costa MB, Cavalcanti Neto PF, Martelli CM et al. (2001) Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study. International Journal of Leprosy and Other Mycobacterial Diseases 69, 177186.
  • DerSimonian R & Laird N (1986) Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177188.
  • Deshmukh AR, Dhurat RS & Jerajani HR (2003) A comparative clinicopathological study of single dose ROM in paucibacillary leprosy patients with 1-3 skin lesions. Indian Journal of Leprosy 75, 209217.
  • Ebenezer GJ & Job CK (1999) Histopathological activity in paucibacillary leprosy patients after ROM therapy. International Journal of Leprosy and Other Mycobacterial Diseases 67, 409413.
  • Egger M, Davey Smith G, Schneider M & Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629634.
  • Emmanuel M & Gupte MD (2005) Lesional characteristics and histopathology in paucibacillary leprosy patients with 2 or 3 skin lesions: comparison between ROM and PB-MDT regimens. Indian Journal of Leprosy 77, 1925.
  • Fine P & Dockrell H (1991) Leprosy vaccines. Vaccine 9, 291293.
  • Franzblau SG & White KE (1990) Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrobial Agents and Chemotherapy 34, 229231.
  • Ganapati R, Revankar CR, Pai VV & Kingsley S (1999) Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up. International Journal of Leprosy and Other Mycobacterial Diseases 67, 308309.
  • Gautam VP (2009) Treatment of leprosy in India. Journal of Postgraduate Medicine 55, 220224.
  • Gelber RH (1987) Activity of minocycline in Mycobacterium leprae-infected mice. Journal of Infectious Diseases 156, 236239.
  • Gelber RH, Fukuda K, Byrd S et al. (1992) A clinical trial of minocycline in lepromatous leprosy. BMJ 304, 9192.
  • Gelber RH, Murray LP, Siu P, Tsang M & Rea TH (1994) Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 62, 568573.
  • Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiologic Reviews, 9, 130.
  • Grosset JH, Guelpa-Lauras CC, Perani EG & Beoletto C (1988) Activity of ofloxacin against Mycobacterium leprae in the mouse. International Journal of Leprosy and Other Mycobacterial Diseases 56, 259264.
  • Grosset JH, Ji BH, Guelpa-Lauras CC, Perani EG & N’Deli LN (1990) Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 58, 281295.
  • Gupte MD (1991) Vaccines against leprosy. Indian Journal of Leprosy 63, 342349.
  • Gupte MD (2000) Field trials of a single dose of the combination rifampicinofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy. Leprosy Review 71(Suppl), S77S80.
  • Gupte MD (2006a) Clinical Trials for Treatment of PB Leprosy Patients with Single Dose of Rifampicin, Ofloxacin and Minocycline (ROM): Final Report – Effectiveness of Single Dose ROM in Paucibacillary Leprosy Patients with 2-5 Skin Lesions. World Health Organization, New Delhi, India.
  • Gupte MD (2006b) Clinical Trials for Treatment of PB Leprosy Patients with Single Dose of Rifampicin, Ofloxacin and Minocycline (ROM): Final Report – Relapse Rates in Single-lesion Paucibacillary Leprosy Cases Treated with Single-dose ROM. World Health Organization, New Delhi, India.
  • Halkin H (1988) Adverse effects of the fluoroquinolones. Reviews of Infectious Diseases 10(Suppl 1), S258S261.
  • Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 17, 112.
  • Ji B (1998) Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Leprosy Review 69, 106109.
  • Ji B, Perani EG, Petinon C & Grosset JH (1992) Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. International Journal of Leprosy and Other Mycobacterial Diseases 60, 556561.
  • Ji B, Jamet P, Perani EG, Bobin P & Grosset JH (1993) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. Journal of Infectious Diseases 168, 188190.
  • Ji B, Perani EG, Petinom C, N’Deli L & Grosset JH (1994) Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrobial Agents and Chemotherapy 38, 662667.
  • Ji B, Perani EG, Petinom C & Grosset JH (1996) Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrobial Agents and Chemotherapy 40, 393399.
  • Ji B, Sow S, Perani E, Lienhardt C, Diderot V & Grosset J (1998) Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrobial Agents and Chemotherapy 42, 11151120.
  • Katoch VM (1998) Is there a microbiological rationale for single-dose treatment of leprosy? Leprosy Review 69, 25.
  • 2-3 Lesion Multicentre Trial Group (2001) A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions. Indian Journal of Leprosy 73, 131143.
  • Levy L, Shepard CC & Fasal P (1976) The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. International Journal of Leprosy and Other Mycobacterial Diseases 44, 183187.
  • Leysen DC, Haemers A & Pattyn SR (1989) Mycobacteria and the new quinolones. Antimicrobial Agents and Chemotherapy 33, 15.
  • Lockwood DN (1997) Rifampicin/minocycline and ofloxacin (ROM) for single lesions – what is the evidence? Leprosy Review 68, 299300.
  • Lockwood DN & Kumar B (2004) Treatment of leprosy. BMJ 328, 14471448.
  • Majumder V, Saha B, Hajra SK, Biswas SK & Saha K (2000) Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion. International Journal of Leprosy and Other Mycobacterial Diseases 68, 283290.
  • Mane I, Cartel J-L & Grosset J-H (1997) Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. International Journal of Leprosy 65, 224229.
  • Martelli CM, Stefani MM, Gomes MK et al. (2000) Single lesion paucibacillary leprosy: baseline profile of the Brazilian Multicenter Cohort Study. International Journal of Leprosy and Other Mycobacterial Diseases 68, 247257.
  • Martelli CMT, Stefani MMA, Gillis TP et al. (2003) Final Report No.60 -Leprosy: Brazil’s leprosy research and control efforts enhanced. http://www.who.int/tdrold/research/finalreps/no60.htm (accessed 22 September 2009).
  • Meima A, Smith WC, van Oortmarssen GJ, Richardus JH & Habbema JD (2004) The future incidence of leprosy: a scenario analysis. Bulletin of the World Health Organization 82, 373380.
  • Namisato M & Ogawa H (2000) Serious side effects of rifampin on the course of WHO/MDT: a case report. International Journal of Leprosy and Other Mycobacterial Diseases 68, 277282.
  • National Institute of Epidemiology (2005) Leprosy Studies. 20–26. http://www.icmr.nic.in/annual/2004-05/nie/leprosy.pdf .
  • Oo KN, Yin NN, Han TT, Wai KT, Myint K & Gyi MM (2008) Serological response to chemoprophylaxis in extended contacts in leprosy – a randomized controlled trial. Nihon Hansenbyo Gakkai Zasshi 77, 310.
  • Pai VV, Bulchand HO, Revankar CR & Ganapati R (1999) Single-dose treatment for paucibacillary leprosy; clinical problems and management. International Journal of Leprosy and Other Mycobacterial Diseases 67, 310312.
  • Pattyn SR (1987) Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice. Antimicrobial Agents and Chemotherapy 31, 671672.
  • Rees RJ, Pearson JM & Waters MF (1970) Experimental and clinical studies on rifampicin in treatment of leprosy. British Medical Journal 1, 8992.
  • Revankar CR, Pai VV, Samy MSA & Ganapati R (1999) Single-dose treatment for paucibacillary leprosy; field implications [4]. International Journal of Leprosy and Other Mycobacterial Diseases 67, 312314.
  • Revankar CR, Bulchand HO, Pai VV & Ganapati R (2002) Single-dose ROM treatment for multilesion paucibacillary leprosy – further observations. International Journal of Leprosy and Other Mycobacterial Diseases 70, 3738.
  • Saito H, Tomioka H & Nagashima K (1986) In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice. International Journal of Leprosy and Other Mycobacterial Diseases 54, 560562.
  • Schuring RP, Richardus JH, Pahan D & Oskam L (2009) Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine 27, 71257128.
  • Sehgal VN, Sardana K & Dogra S (2008) The imperatives of leprosy treatment in the pre-and post-global leprosy elimination era: appraisal of changing the scenario to current status. The Journal of Dermatological Treatment 19, 8291.
  • Setia MS, Steinmaus C, Ho CS & Rutherford GW (2006) The role of BCG in prevention of leprosy: a meta-analysis. The Lancet Infectious Diseases 6, 162170.
  • Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M & Ciampi A (2010) Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Alternative Therapies in Health and Medicine 16, 3644.
  • Shepard CC, Walker LL, Van Landingham M & Redus MA (1971) Kinetic testing of drugs against Mycobacterium leprae in mice. Activity of cephaloridine, rifampin, streptovaricin, vadrine, and viomycin. American Journal of Tropical Medicine and Hygiene 20, 616620.
  • Shepard CC, Levy L & Fasal P (1972) Rapid bactericidal effect of rifampin on Mycobacterium leprae. American Journal of Tropical Medicine and Hygiene 21, 446449.
  • Shepard CC, Levy L & Fasal P (1974) Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae. American Journal of Tropical Medicine and Hygiene 23, 11201124.
  • Shinde A, Khopkar U & Pai VV (2000) Single-dose treatment for single lesion leprosy; histopathological observations [4]. International Journal of Leprosy and Other Mycobacterial Diseases 68, 328330.
  • Shukla P, Miranda MS, Prabhudesai R & Rege VL (2002) Single dose ROM therapy in Goa. Indian Journal of Leprosy 74, 169172.
  • Single-lesion Multicentre Trial Group (1997) Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. Indian Journal of Leprosy 69, 121129.
  • Song F, Eastwood AJ, Gilbody S, Duley L & Sutton AJ (2000) Publication and related biases. Health Technology Assessment 4, 1115.
  • Sousa AL, Stefani MM, Pereira GA et al. (2007) Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. American Journal of Tropical Medicine and Hygiene 77, 829833.
  • Stanford JL (1994) The history and future of vaccination and immunotherapy for leprosy. Tropical and Geographical Medicine 46, 93107.
  • Talwar GP (1985) Vaccines against leprosy. Asian Pacific Journal of Allergy and Immunology 3, 137139.
  • Ura S, Diório SM, Carreira BG et al. (2007) Estudo terapêutico comparando a associação de Rifampicina, Ofloxacina e Minociclina com a associação Rifampicina, Clofazimina e Dapsona em pacientes com Hanseníase multibacilar. Hansenologica Internationalis 32, 5765.
  • Vijayakumaran P, Manimozhi N, Jesudasan K, Arunthathi S, Jacob M & Samuel P (1997) Leucocytopenia after rifampicin and ofloxacin therapy in leprosy. Leprosy Review 68, 1015.
  • Villahermosa LG, Fajardo TT Jr, Abalos RM et al. (2004) Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. American Journal of Tropical Medicine and Hygiene 70, 197200.
  • Visschedijk J, van de Broek J, Eggens H, Lever P, van Beers S & Klatser P (2000) Mycobacterium leprae – millennium resistant! Leprosy control on the threshold of a new era. Tropical Medicine and International Health 5, 388399.
  • World Health Assembly (1991) Elimination of Leprosy: resolution of the 44th World Health Assembly. World Health Assembly.
  • World Health Organization (1982) Chemotherapy of Leprosy for Control Programmes (No. 675). World Health Organization.
  • World Health Organization (1998) WHO Expert Committee on Leprosy (1997). World Health Organization, Geneva.
  • World Health Organization (2010a) Global leprosy situation. Weekly epidemiological record. http://www.who.int/wer/2010/wer8535.pdf (accessed 19 October 2010).
  • World Health Organization (2010b) Leprosy elimination. http://www.who.int/lep/en/index.html (accessed 19 October 2010).
  • World Health Organization (2010c) WHO Multidrug therapy (MDT). http://www.who.int/lep/mdt/en/ (accessed 20 October 2010).
  • World Health Organization (2010d) WHO recommended MDT regimens. http://www.who.int/lep/mdt/regimens/en/index.html (accessed 20 October 2010).